Vertex Pharmaceuticals Incorporated
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Vertex Pharmaceuticals Incorporated (VRTX), headquartered in Boston, Massachusetts and founded in 1989, develops, manufactures and commercializes transformative medicines for serious diseases, with a primary focus on cystic fibrosis, sickle cell disease, beta thalassemia and emerging areas including pain, kidney disease and type 1 diabetes; its portfolio features the CFTR modulators TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO, the CRISPR/Cas9 gene-edited therapy CASGEVY (co-developed with CRISPR Therapeutics), the non-opioid NaV1.7 pain treatment JOURNAVX/suzetrigine, and investigational assets such as povetacicept (for IgA nephropathy and other autoimmune kidney diseases), inaxaplin (for APOL1-mediated kidney disease), VX-407 (for autosomal dominant polycystic kidney disease), VX-522 (CFTR mRNA therapy with Moderna), VX-880/VX-264 (stem cell therapies for type 1 diabetes) and VX-993 (next-generation pain candidate); the company operates research facilities in San Diego, California and Milton Park, Oxfordshire, UK, with commercial presence across North America, Europe, Australia, Asia and the Middle East. In recent developments, Vertex completed its $4.9 billion acquisition of Alpine Immune Sciences in 2024 to secure povetacicept, entered an exclusive collaboration with Ono Pharmaceutical in June 2025 for povetacicept commercialization in Japan and South Korea (building on a prior deal with Zai Lab), launched ALYFTREK in the US and began European reimbursement efforts in England, Germany and Denmark, advanced CASGEVY and JOURNAVX launches with expanding US coverage including major PBMs and hospital networks, completed Phase 3 enrollment for povetacicept in IgA nephropathy (targeting accelerated US approval in H1 2026), initiated VX-407 Phase 2 proof-of-concept for ADPKD, progressed VX-522 Phase 1/2 data readout in H1 2025 and discontinued standalone development of an experimental pain drug following mid-stage failure while prioritizing suzertrigine/JOURNAVX expansion. Vertex reported Q3 2025 total revenues of $3.08 billion (up 11% year-over-year), driven by CF franchise growth, early new product contributions and favorable US pricing, with full-year 2025 guidance refined to $11.9-12.0 billion.
ABN Amro Investment Solutions Grows Holdings in Vertex Pharmaceuticals Incorporated $VRTX
Andra AP fonden Has $10.67 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX
Amova Asset Management Americas Inc. Cuts Holdings in Vertex Pharmaceuticals Incorporated $VRTX
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today
Boston Common Asset Management LLC Has $7.68 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX
Broderick Brian C Purchases 1,454 Shares of Vertex Pharmaceuticals Incorporated $VRTX
Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching
Assetmark Inc. Has $26.77 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
Is This Biotech Stock a Buy Near Its 52-Week High?
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?
Why Crinetics Stock Soared 99% This Week
Jim Cramer Says Biotech is The Hottest Group in The Market Right Now
Nvidia, Vertex Pharmaceuticals And More On CNBC's ‘Final Trades'
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX
Vertex's Crinetics Deal Balances Growth with Integration Risk